Standout Papers

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myel... 2016 2026 2019 2022 342
  1. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2016)
    Claire Harrison, Alessandro M. Vannucchi et al. Leukemia

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 60 standout
Sub-graph 1 of 24

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Interferon- γ and infectious diseases: Lessons and prospects
2024 StandoutScience
3 intermediate papers

Works of L. Knoops being referenced

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
2016 Standout
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
2011

Author Peers

Author Last Decade Papers Cites
L. Knoops 415 330 275 13 612
Teresa Davies 333 473 205 9 693
Kim Champion 306 519 140 15 730
Sachie Marubayashi 422 304 350 11 688
Jean Michel Cayuela 402 470 130 12 712
Matthew S. Zabriskie 291 405 299 24 698
Mario Lazzarino 420 502 250 12 688
A B Deisseroth 283 430 109 10 579
P. Gopalakrishna 467 375 265 7 602
Jianmin Ding 256 257 394 17 733
Yi-Hsiang Chen 287 336 323 11 668

All Works

Loading papers...

Rankless by CCL
2026